CAMP4 Therapeutics Corporation
NASDAQ:CAMPBiotechnology
+$0.10 today
- Market cap
- $257.29M
- Beta
- 0.08
- P/E (TTM)
- -2.8
- EPS (TTM)
- -$1.49
Volume 0.19M
Average 0.10M
CAMP Depreciation & Amortization
Non-cash expense that spreads the cost of physical and intangible assets over their useful lives.
CAMP4 Therapeutics CorporationNASDAQ: CAMP
Depreciation & Amortization · Q1 FY2026 · quarter ended Mar 2026
Depreciation & amortization growth accelerates
Q1 FY2026 depreciation & amortization of $520K rose 23.5% year over year, ahead of the +3.4% change in trailing-twelve-month depreciation & amortization. Sequentially, it rose 39.8% from the prior quarter.
Context
- Depreciation & amortization amounted to 46.9% of revenue in FY2025, down 213.3 pp from a year earlier.
- Depreciation & amortization increased in 2 of the last 3 fiscal years.
What to watch
Whether quarterly growth of +23.5% holds above the trailing-twelve-month pace of +3.4%.
Sources:Income StatementText generated from reported figures; not investment advice.
Depreciation & Amortization history
USD · from the income statement
- Latest · FY2025
- 1.64M USD
- Year-over-year change
- -3.4%
- 4-year CAGR
- -48.2%
| Period | Period end | Depreciation & Amortization | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 1.64M | -3.4% |
| FY2024 | 2024-12-31 | 1.7M | +1.1% |
| FY2023 | 2023-11-30 | 1.68M | +91.1% |
| FY2022 | 2023-02-28 | 878K | -96.1% |
| FY2021 | 2022-02-28 | 22.8M | — |
Depreciation & Amortization vs competitors
How CAMP compares with its peers on the latest reported figures
- Peers report in different currencies, so depreciation & amortization is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of +3.4% is the 3rd highest of 9, against a peer median of -21.1%.
- Depreciation & amortization amounts to 44.2% of revenue for CAMP, versus a peer median of 12.4%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $7.46M USD | -16.4% | +13.9% | 2.9% | |
HYFTMindWalk Holdings Corp. | LTM Jan 2026 | CA$2.28M CAD | -60.7% | +10.7% | 12.4% |
| LTM Mar 2026 | $1.74M USD | +3.4% | — | 44.2% | |
ACRVAcrivon Therapeutics, Inc. Common Stock | LTM Mar 2026 | $1.39M USD | +27.4% | +55.0% | — |
| LTM Mar 2026 | $1.34M USD | +0.8% | -2.9% | 705.3% | |
| LTM Mar 2026 | $1.02M USD | -43.2% | +26.8% | — | |
| LTM Mar 2026 | $648K USD | +144.5% | +52.6% | — | |
| LTM Mar 2026 | $645K USD | -25.8% | +27.3% | — | |
| LTM Mar 2026 | $130K USD | -84.1% | -41.1% | — | |
| Peer median (excluding CAMP) | — | -21.1% | +20.4% | 12.4% | |
Competitors are the stored peer set for CAMP. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Feb 2022 | FY2022 Feb 2023 | FY2023 Nov 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 295.84M | 0 | 350K | 652K | 3.5M |
| Cost of Revenue | 173.95M | 0 | 0 | 0 | 1.64M |
| Gross Profit | 121.89M | (947K) | 350K | 652K | 1.86M |
| Gross Margin | 41.2% | — | 100.0% | 100.0% | 53.1% |
| Research & Development | 28.44M | 34.77M | 40.62M | 38.82M | 38.2M |
| Selling, General & Admin | 100.9M | 10.23M | 11.61M | 14.92M | 17.36M |
| Operating Expenses | 134.76M | 45M | 52.23M | 53.74M | 53.92M |
| Depreciation & Amortization | 22.8M | 878K | 1.68M | 1.7M | 1.64M |
| EBITDA | 7.49M | (44.12M) | (50.2M) | (51.39M) | (50.42M) |
| EBITDA Margin | 2.5% | — | -14343.1% | -7882.2% | -1441.5% |
| Operating Income | (15.31M) | (45M) | (51.88M) | (53.09M) | (52.06M) |
| Operating Margin | -5.2% | — | -14822.6% | -8142.3% | -1488.3% |
| Interest Income | 0 | 0 | 2.81M | 1.33M | 2.17M |
| Interest Expense | 15.32M | 6.26M | 0 | 0 | 0 |
| Other Income / Expenses | (14.75M) | 809K | 2.59M | 1.3M | (28.34M) |
| Income Before Tax | (30.06M) | (44.19M) | (49.29M) | (51.79M) | (80.4M) |
| Pre-Tax Margin | -10.2% | — | -14083.1% | -7943.4% | -2298.5% |
| Income Tax Expense | 1.09M | 0 | 0 | 0 | 0 |
| Net Income | (31.15M) | (44.19M) | (49.29M) | (51.79M) | (80.4M) |
| Net Margin | -10.5% | — | -14083.1% | -7943.4% | -2298.5% |
| EPS (Basic) | (0.88) | (0.90) | (4.07) | (2.66) | (2.65) |
| EPS (Diluted) | (0.88) | (0.90) | (4.07) | (2.66) | (2.65) |
| Weighted Avg Shares | 35.25M | 36.1M | 12.12M | 19.51M | 30.38M |
| Weighted Avg Shares (Diluted) | 35.25M | 36.13M | 12.12M | 19.51M | 30.38M |
CAMP4 Therapeutics Corporation
NASDAQ:CAMP
Intrinsic Alpha fair value
Locked
Current Price
$4.10
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.